Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity

BACKGROUND: Several large clinical trials have confirmed the cardioprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes. However, whether empagliflozin, as an SGLT2i, could alleviate atherosclerosis progression in non-diabetic states remain unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yihai, Xu, Jiamin, Wu, Mingyue, Xu, Biao, Kang, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802233/
https://www.ncbi.nlm.nih.gov/pubmed/33436015
http://dx.doi.org/10.1186/s12944-021-01430-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802233/
https://www.ncbi.nlm.nih.gov/pubmed/33436015
http://dx.doi.org/10.1186/s12944-021-01430-y

Ejemplares similares